Vivani Medical Gives Data for Weight Loss Implant
By Karen Roman
Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for chronic weight management, with expected once or twice-yearly dosing.
The results support the company’s NanoPortal implant for delivery of therapeutic molecules for obesity and type 2 diabetes, Vivani stated.
“This preclinical demonstration of NPM-139 comes on the heels of having rapidly enrolled and successfully implanted an initial group of subjects in LIBERATE-1, our first-in-human study with NPM-115, which we expect will pave the road for NPM-139 as development continues for both programs,” said Adam Mendelsohn, Ph.D., Vivani Medical’s CEO.
Contact:
Editor@executives-edge.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10